EUVIMEDEUVIMED entdecken
Crossref

Management of Sarcoidosis in Older Adults: Balancing Disease Activity, Toxicity, and Comorbidity

Jasmine Vakhshoorzadeh, Mohamed I. Seedahmed, Mazen O. Al-Qadi

Advances in Geriatric Medicine and Research · 04.08.2026 · 8 (4)

DOI: 10.20900/agmr20260035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Geriatric Medicine and Research, online erschienen am 04.08.2026. Verfasst von Jasmine Vakhshoorzadeh und 2 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sarcoidosis is a multisystem granulomatous disease with a heterogeneous clinical course that ranges from spontaneous resolution to chronic, stable disease or progressive organ damage. Traditionally considered a disease of younger and middle-aged adults, sarcoidosis is increasingly recognized in older adults, either as late-onset disease or as chronic sarcoidosis persisting into later life. This has major clinical implications because older patients frequently have comorbidities, reduced physiologic reserve, frailty, polypharmacy, and increased susceptibility to treatment-related toxicity. Late-onset sarcoidosis appears to differ from younger-onset disease in several clinically relevant ways, including stronger female predominance, fewer classic presentations, more frequent extrapulmonary involvement, and lower remission rates. Treatment decisions in older adults require careful assessment of organ involvement, disease activity, risk of progression, and the anticipated benefit of immunosuppression relative to potential harm. Glucocorticoids remain effective for rapid disease control but carry substantial risks in older patients, including hyperglycemia, osteoporosis, infection, myopathy, neuropsychiatric effects, and functional decline. Earlier use of steroid-sparing therapy, careful medication reconciliation, infection-risk mitigation, and longitudinal monitoring for both disease progression and treatment toxicity are essential. Future studies should specifically include adults aged 65 years and older and evaluate outcomes beyond lung function and imaging, including infections, falls, hospitalization, treatment discontinuation, quality of life, functional status, and maintenance of independence.

Zitieren

APA

Vakhshoorzadeh, J., Seedahmed, M. I., & Al-Qadi, M. O. (2026). Management of Sarcoidosis in Older Adults: Balancing Disease Activity, Toxicity, and Comorbidity. Advances in Geriatric Medicine and Research, 8(4). https://doi.org/10.20900/agmr20260035

Vancouver

Vakhshoorzadeh J, Seedahmed MI, Al-Qadi MO. Management of Sarcoidosis in Older Adults: Balancing Disease Activity, Toxicity, and Comorbidity. Advances in Geriatric Medicine and Research. 2026;8(4). doi:10.20900/agmr20260035

BibTeX
@article{Vakhshoorzadeh2026,
  author = {Vakhshoorzadeh, Jasmine and Seedahmed, Mohamed I. and Al-Qadi, Mazen O.},
  title = {Management of Sarcoidosis in Older Adults: Balancing Disease Activity, Toxicity, and Comorbidity},
  journal = {Advances in Geriatric Medicine and Research},
  year = {2026},
  volume = {8},
  number = {4},
  doi = {10.20900/agmr20260035}
}
Kostenlos starten →